3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Breast
2
Thoracic
1
NET
1
Lymphoid
1
Head & Neck
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Sunitinib
3
telotristat ethyl
1
romidepsin
1
lutetium Lu 177 dotatate
1
gallium Ga 68 dotatate
1
folfirinox
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
copper dotatate CU-64
1
alectinib
1
Temozolomide
1
TH 302
1
Quality of Life
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Plastic Surgery Procedures
1
Patient Reported Outcome Measures
1
Needles
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Lutetium-177
1
Lutetium
1
Lactones
1
Immunotherapy
1
Granulocyte Colony-Stimulating Factor
1
Fluorodeoxyglucose F18
1
Filgrastim
1
FAPI-46
1
Everolimus
1
Drug Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
alectinib
×
NET
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts